362亿！增长22.8%！波士顿科学季报发布

Core Viewpoint - Boston Scientific reported strong financial performance in Q2 2025, with sales of $5.061 billion, a year-over-year increase of 22.8%, driven primarily by its Cardiovascular and MedSurg segments [1][2]. Financial Performance - The company achieved net sales of $5.061 billion, exceeding analyst expectations of $4.89 billion, with an operational growth of 21.6% and organic growth of 17.4%, surpassing the previous guidance of 13%-15% [2][4]. - GAAP net profit reached $797 million, translating to an EPS of $0.53, more than doubling from $324 million (EPS of $0.22) in the same period last year [2][4]. - Adjusted EPS was $0.75, higher than the company's prior guidance of $0.71–$0.73 and market consensus of $0.73 [2][4]. - The company raised its full-year revenue growth guidance from 15%-17% to 18%-19% and adjusted EPS expectations from $2.87–$2.94 to $2.95–$2.99 [2]. Business Segment Performance - The Cardiovascular segment was the main growth driver, with sales of $3.345 billion, a 26.8% increase year-over-year [3][5]. - The MedSurg segment generated $1.716 billion in sales, reflecting a 15.7% year-over-year growth [3][6]. - Key contributors to Cardiovascular growth included electrophysiology and structural heart disease treatments, while MedSurg saw stable performance across urology, digestion, and neuromodulation [3][6][7]. Product and Regulatory Progress - The Farapulse system received FDA approval for expanded indications, and the company initiated clinical trials to evaluate its effectiveness in patients with recurrent atrial fibrillation [10][12]. - The Watchman FLX Pro device received CE mark certification in the EU, enhancing its clinical adoption potential [14]. Market Environment and Policy Changes - The CMS proposal to include catheter ablation procedures in outpatient surgery center payment coverage could significantly enhance patient access and affordability, benefiting the deployment of Farapulse and Watchman [15]. Strategic Acquisitions - Boston Scientific completed acquisitions of three medical technology companies, focusing on interventional oncology, chronic disease treatment, and vascular disease, which align with its existing business and enhance its product pipeline [16].